ALTo endogrAft Italian Registry
Launched by GIANMARCO DE DONATO · Feb 8, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The ALTo endogrAft Italian Registry is a clinical trial aimed at evaluating the safety and effectiveness of a specific treatment called the ALTO stent graft for patients with an abdominal aortic aneurysm (AAA). An AAA is a bulge in the large blood vessel that supplies blood to the body, which can be life-threatening if it breaks. This trial is looking at the results of the treatment during and after surgery to see how well it works over time.
To participate in this study, patients must be at least 18 years old and are scheduled for a planned (not emergency) surgery to repair their AAA using the ALTO device. Participants will need to agree to follow-up appointments to monitor their health after the procedure. It's important to note that people who have had urgent surgeries, certain health conditions, or a history of severe reactions to contrast dye used in imaging tests may not be eligible. By joining this study, participants can contribute valuable information to help improve AAA treatment outcomes for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Elective AAA patients that should be treated by standard EVAR, according to Endologix Alto endograft device's Instructions For Use;
- • Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study;
- • Patient is \>18 years old;
- • Patient, or their legal representative, understands the nature of the procedure and provides written informed consent, prior to enrollment in the study.
- Exclusion Criteria:
- • EVAR performed in Urgent/Emergent setting;
- • Patients treated outside Endologix Alto endograft device's Instructions For Use;
- • Patients refusing treatment;
- • Patients for whom antiplatelet therapy, anticoagulants or antihypertensive drug are contraindicated;
- • Patients with a history of prior life-threatening contrast medium reaction;
- • Life expectancy of less than follow-up period.
- • AAA: abdominal aortic aneurysm; EVAR: abdominal endovascular aneurysm
About Gianmarco De Donato
Gianmarco De Donato is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a strong focus on enhancing patient outcomes, the organization designs and oversees clinical trials that adhere to the highest ethical and scientific standards. Leveraging a multidisciplinary team of experts, Gianmarco De Donato fosters collaboration with healthcare professionals, regulatory bodies, and industry partners to ensure the successful development of groundbreaking therapies. Their commitment to transparency and rigorous data analysis ensures that every trial contributes valuable insights to the medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Siena, , Italy
Rome, , Italy
Patients applied
Trial Officials
Gianmarco de Donato, MD, PhD
Principal Investigator
University of Siena
Maurizio Taurino, MD, PhD
Principal Investigator
University La Sapienza of Rome
Francesco Talarico, MD, PhD
Principal Investigator
Ospedale Civico di Palermo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials